Reovirus and tumor oncolysis

Journal of Microbiology

Volumn 45, Issue 3, 2007, Pages 187-192

  Kim, Manbok ^a   Chung, Young Hwa ^b   Johnston, Randal N ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b Pusan National University   (South Korea)

Author keywords

Oncogene signaling; Persistent infection; Reovirus; Viral attenuation; Viral oncolysis; Viral pathogenesis

Indexed keywords

ONCOLYTIC VIRUS;

ANIMAL; HUMAN; MOUSE; ONCOLYTIC VIROTHERAPY; PATHOGENICITY; PHYSIOLOGY; REOVIRUS; REVIEW;

ANIMALS; HUMANS; MICE; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; REOVIRIDAE;

ANIMALIA; MUS; ORTHOREOVIRUS; REOVIRIDAE;

EID: 34447132877     PISSN: 12258873     EISSN: 12258873     Source Type: Journal    
DOI: None     Document Type: Review

References (62)

1. Ahmed, M., S.D. Cramer, and D.S. Lyles. 2004. Sensitivity of prostate tumors to wild type and M protein mutant vesicular stomatitis viruses. Virology 330, 34-49.
2. Ahmed, R., W.M. Canning, R.S. Kauffman, A.H. Sharpe, J.V. Hallum, and B.N. Fields. 1981. Role of the host cell in persistent viral infection: coevolution of L cells and reovoirus during persistent infection. Cell 25, 325-332.
3. Alain, T., J.F. Wong, S. Urbanski, P. Lee, A.E. Kossakowska, R.N. Johnston, and P.L. Beck. 2007. Reovirus decreases azoxymethane-induced aberrant crypt foci and colon cancer in a rodent model. Cancer Gene Ther. (in press).
4. Alain, T., M. Kim, R.N. Johnston, S.J. Urbanski, A.E. Kossakowska, P.A.J. Forsyth, and P.W.K. Lee. 2006. The oncolytic effect in vivo of reovirus on tumour cells that have survived reovirus cell killing in vitro. Br. J. Cancer 95, 1020-1027.
5. Baer, G.S, D.H. Ebert, C.J. Chung, A.H. Erickson, and T.S. Dermody. 1999. Mutant cells selected during persistent reovirus infection do not express mature cathepsin L and do not support reovirus disassembly. J. Virol. 73, 9532-9543.
6. Baty, C.J. and B. Sherry. 1993. Cytopathogenic effect in cardiac myocytes but not in cardiac fibroblasts is correlated with reovirus-induced acute myocarditis. J. Virol. 67, 6295-6298.
7. Bischoff, J.R., D.H. Kirn, A.Williams, C. Heise, S. Horn, M. Muna, L. Ng, J.A. Nye, A. Sampson-Johannes, A. Fattaey, and F. McCormick. 1996. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274, 373-376.
8. Bos, J.L. 1989. Ras oncogenes in human cancer: a review. Cancer Res. 49, 4682-4689.
9. Carroll, P.E, M. Okuda, H.F. Horn, P. Biddinger, P.J. Stambrook, L.L. Gleich, Y.Q. Li, P. Tarapore, and K. Fukasawa. 1999. Centrosome hyperamplification in human cancer: chromosome instability induced by p53 mutation and/or Mdm2 overexpression. Oncogene 18, 1935-1944.
10. Coffey, M.C., J.E. Strong, P.A. Forsyth, and P.W. Lee. 1998. Reovirus therapy of tumors with activated Ras pathway Science 282, 1332-1334.
11. DeBiasi, R.L., B.A. Robinson, B. Sherry, R. Bouchard, R.D. Brown, M. Rizeq, C. Long, and K.L. Tyler. 2004. Caspase inhibition protects against reovirus-induced myocardial injury in vitro and in vivo. J. Virol. 78, 11040-11050.
12. Dermody, T.S. 1998. Molecular mechanisms of persistent infection by reovirus. Curr. Top Microbiol. Immunol. 233(Pt 2), 1-22.
13. Dichter, M.A. and H.L. Weiner. 1984. Infection of neuronal cell cultures with reovirus mimics in vitro patterns of neurotropism. Ann. Neurol. 16, 603-610.
14. Duncan, M.R., S.M. Stanish, and D.C. Cox. 1978. Differential sensitivity of normal and transformed human cells to reovirus infection. J. Virol. 28, 444-449.
15. Duursma, A.M. and R. Agami. 2003. Ras interference as cancer therapy. Semin. Cancer Biol. 13, 267-273.
16. Ebert, D.H, S.A. Kopecky-Bromberg, and T.S. Dermody. 2004. Cathepsin B is inhibited in mutant cells selected during persistent reovirus infection. J. Biol. Chem. 279, 3837-3851.
17. Ebert, O., S. Harbaran, K. Shinozaki, and S.L. Woo. 2005. Systemic therapy of experimental breast cancer metastases by mutant vesicular stomatitis virus in immune-competent mice. Cancer Gene Ther. 12, 350-358.
18. Egan, C., M. Kim, and R.N. Johnston. 2003. Increased expression of human c-Myc renders cells sensitive to reovirus oncolysis. AACR Annual General Meeting, Washington, D.C., USA.
19. Haller, B.L, M.L. Barkon, G.P. Vogler, and H.W. Virgin 4th. 1995. Genetic mapping of reovirus virulence and organ tropism in severe combined immunodeficient mice: organ-specific virulence genes. J. Virol. 69, 357-364.
20. Hashiro, G., P.C. Loh, and J.T. Yau. 1977. The preferential cytotoxicity of reovirus for certain transformed cell lines. Arch. Virol. 54, 307-315.
21. Heggie, A.D. and L. Gaddis. 1979. Effects of viral exposure of the two-cell mouse embryo on cleavage and blastocyst formation in vitro. Pediatr. Res. 13, 937-941.
22. Heinzerling, L., V. Kunzi, P.A. Oberholzer, T. Kundig, H. Naim, and R. Dummer. 2005. Oncolytic measles virus in cutaneous T-cell lymphomas mounts antitumor immune responses in vivo and targets interferon-resistant tumor cells. Blood 106, 2287-2294.
23. Heise, C., T. Hermiston, L. Johnson, G. Brooks, A. Sampson-Johannes, A. Williams, L. Hawkins, and D. Kirn. 2000. An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nat. Med. 6, 1134-1139.
24. Jackson, G.G. and R.L. Muldoon. 1973. Viruses causing common respiratory infection in man. IV. Reoviruses and adenoviruses. J. Infect. Dis. 128, 811-833.
25. Jun, H.S. and J.W. Yoon. 2003. A new look at viruses in type 1 diabetes. Diabetes Metab. Res. Rev. 19, 8-31.
26. Kim, J.H., Y.S. Lee, H. Kim, J.H. Huang, A.R. Yoon, and C.O. Yun. 2006. Relaxin expression from tumor-targeting adenoviruses and its intratumoral spread, apoptosis induction and efficacy. J. Natl. Cancer Inst. 98, 1482-1493.
27. Kim, M. 2005. Mechanisms of resistance to reoviral oncolysis. Ph. D. Thesis. University of Calgary, Alberta, Canada.
28. Kim, M., C. Egan, T. Alain, S.J. Urbanski, P.W.K. Lee, P.A.J. Forsyth, and R.N. Johnston. 2007a. Acquired resistance to reoviral oncolysis in Ras-transformed fibrosarcoma cells. Oncogene 26, 4124-4134.
29. Kim, M., N. Nieden, S.D. Loken, S.J. Urbanski, P.W.K. Lee, D.E. Rancourt, and R.N. Johnston. 2007b. Safety of attenuated reovirus on the developmental potential of embryonic stem cells. The 4th International Conference on Oncolytic Viruses As Cancer Therapeutics. Scottsdale, AZ, USA.
30. Kim, M., T. Alain, S.J. Urbanski, A.E. Kossakowska, P.W.K. Lee, P.A.J. Forsyth, and R.N. Johnston. 2007c. An attenuated reovirus isolated from persistent reovirus infection exerts viral oncolysis with reduced pathogenicity. The 4th International Conference on Oncolytic Viruses As Cancer Therapeutics. Scottsdale, AZ, USA.
31. Kirn, D. 2001. Oncolytic virotherapy for cancer with the adenovirus dl1520 (Onyx-015): results of phase I and II trials. Expert Opin. Biol. Ther. 1, 525-538.
32. Loken, S.D., K. Norman, K. Hirasawa, M. Nodwell, W.M. Lester, and D.J. Demetrick. 2004. Morbidity in immunosuppressed (SCID/NOD) mice treated with reovirus (dearing 3) as an anticancer biotherapeutic. Cancer Biol. Ther. 3, 734-738.
33. Lun, X., W. Yang, T. Alain, Z.Q. Shi, H. Muzik, J.W. Barrett, G. McFadden, J. Bell, M.G. Hamilton, D.L. Senger, and P.A. Forsyth. 2005. Myxoma virus is a novel oncolytic virus with significant antitumor activity against experimental human gliomas. Cancer Res. 65, 9982-9990.
34. Mann, M.A, K.L. Tyler, D.M Knipe, and B.N. Fields. 2002. Type 3 reovirus neuroinvasion after intramuscular inoculation: viral genetic determinants of lethality and spinal cord infection. Virology 303, 213-221.
35. McFadden, G. 2005. Poxvirus tropism. Nat. Rev. Microbiol. 3, 201-213.
36. Minuk, G.Y., N. Rascanin, R.W. Paul, P.W. Lee, K. Buchan, and J.K. Kelly. 1987. Reovirus type 3 infection in patients with primary biliary cirrhosis and primary sclerosing cholangitis. J. Hepatol. 5, 8-13.
37. Minuk, G.Y., R.W. Paul, and P.W. Lee. 1985. The prevalence of antibodies to reovirus type 3 in adults with idiopathic cholestatic liver disease. J. Med. Virol. 16, 55-60.
38. Morris, S.M. 2002. A role for p53 in the frequency and mechanism of mutation. Mutat. Res. 511, 45-62.
39. Nakamura, T. and S.J. Russell. 2004. Oncolytic measles viruses for cancer therapy. Expert Opin. Biol. Ther. 4, 1685-1692.
40. Nibert, M.L. and L.A. Schiff. 2001. Reoviruses and their replication. p. 1679-1728, In B.N. Fields, D.M Knipe, and P.M. Howley, (eds.). Fields Virology, Lippincott-Raven Publisher, Philadelphia, USA.
41. Norman, K.L. and P.W. Lee. 2005. Not all viruses are bad guys: the case for reovirus in cancer therapy. Drug Discov. Today 10, 847-855.
42. Priscott, P.K. 1983. The growth of reovirus 3 in cultured rat embryos and implications for human reproductive failure. Br. J. Exp. Pathol. 64, 467-473.
43. Richardson, S.C., R.F. Bishop, and A.L. Smith. 1994. Reovirus serotype 3 infection in infants with extrahepatic biliary atresia or neonatal hepatitis. J. Gastroenterol. Hepatol. 9, 264-268.
44. Ring, C.J. Cytolytic viruses as potential anti-cancer agents. 2002. J. Gen. Virol. 83, 491-502.
45. Rosen, L., H.E. Evans, and A. Spickard. 1963. Reovirus infections in human volunteers. Am. J. Epidemiol. 77, 29-37.
46. Roberts, M.S., R.M. Lorence, W.S. Groene, and M.K. Bamat. 2006. Naturally oncolytic viruses. Curr. Opin. Mol. Ther. 8, 314-321.
47. Russell, S.J. 2002. RNA viruses as virotherapy agents. Cancer Gene Ther. 9, 961-966.
48. Sabin, A.B. 1959. Reoviruses. A new group of respiratory and enteric viruses formerly classified as ECHO type 10 is described. Science 130, 1387-1389.
49. Steele, T.A. and C.C Hauser. 2005. The role of interferon-alpha in a successful murine tumor therapy. Exp. Biol. Med. 230, 487-493.
50. Steele, T.A. and D.C. Cox. 1995. Reovirus type 3 chemoimmunotherapy of murine lymphoma is abrogated by cyclosporine. Cancer Biother. 10, 307-315.
51. Stoeckel, J. and J.G. Hay. 2006. Drug evaluation: Reolysin-wild-type reovirus as a cancer therapeutic. Curr. Opin. Mol. Ther. 8, 249-260.
52. Stojdl, D.F., B. Lichty, S. Knowles, R. Marius, H. Atkins, N. Sonenberg, and J.C. Bell. 2000. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat. Med. 6, 821-825.
53. Stojdl, D.F., B.D. Lichty, B.R. TenOever, J.M. Paterson, A.T. Power, S. Knowles, R. Marius, J. Reynerd, L. Poliquin, H. Atkins, E.G. Brown, R.K. Durbin, J.E. Durbin, J. Hiscott, and J.C. Bell. 2003. VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell. 4, 263-275.
54. Strong, J.E., M.C. Coffey, D. Tang, P. Sabinin, and P.W. Lee. 1998. The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus. EMBO J. 17, 3351-3362.
55. Strong, J.E. and P.W. Lee. 1996. The v-erbB oncogene confers enhanced cellular susceptibility to reovirus infection. J. Virol. 70, 612-616.
56. Takai, Y., T. Sasaki, and T. Matozaki. 2001. Small GTP-binding proteins. Physiol. Rev. 81, 153-208.
57. Terheggen, F., E. Benedikz, P.H. Frissen, and K. Brinkman. 2003. Myocarditis associated with reovirus infection. Eur. J. Clin. Microbiol. Infect. Dis. 22, 197-198.
58. Thorne, S.H., D.L. Bartlett, and D.H. Kirn. 2005. The use of oncolytic Vaccinia viruses in the treatment of cancer: a new role for an old ally? Curr. Gene Ther. 5, 429-443.
59. Tyler, K.L. 2001. Mammalian reoviruses, p. 1729-1745. In B.N. Fields, D.M. Knipe, and P.M. Howley (eds), Fields Virology, Lippincott-Raven, Philadelphia, USA.
60. Wang, G., J.W. Barrett, M. Stanford, S.J. Werden, J.B. Johnston, X. Gao, M. Sun, J.Q. Cheng, and G. McFadden. 2006. Infection of human cancer cells with myxoma virus requires Akt activation via interaction with a viral ankyrin-repeat host range factor. Proc. Natl. Acad. Sci. USA 103, 4640-4645.
61. Weiner, H.L., D. Drayna, D.R. Averill, Jr., and B.N. Fields. 1977. Molecular basis of reovirus virulence: role of the S1 gene. Proc. Natl. Acad. Sci. USA 74, 5744-5748.
62. Weiner, H.L., M.L. Powers, and B.N. Fields. 1980. Absolute linkage of virulence and central nervous system cell tropism of reoviruses to viral hemagglutinin. J. Infect. Dis. 141, 609-616.